Urology
Volume 73, Issue 3 , Pages 470-472 , March 2009

Why External Beam Radiotherapy Is Treatment of Choice for Most Men With Early-stage Nonmetastatic Prostate Cancer

  • Eric M. Horwitz, M.D.

      Affiliations

    • Corresponding Author InformationReprint requests: Eric M. Horowitz, M.D. Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottnan Avenue, Philadelphia, PA 19111

Received 3 September 2008 ,Accepted 27 September 2008.

References 

  1. Potters L, Morgenstern C, Calugaru E, et al. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2005;173:1562–1566
  2. D'Ambrosio DJ, Pollack A, Harris EE, et al. Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:671–677
  3. Stone N, Potters L, Davis B, et al. Customized dose prescription for prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys. 2007;69:1472–1477
  4. Kupelian P, Kuban D, Thames H, et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys. 2005;61:415–419
  5. Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007;67:327–333
  6. Eade TN, Horwitz EM, Ruth K, et al. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant. Int J Radiat Oncol Biol Phys. 2008;71:338–345
  7. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO, Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  8. Zelefsky MJ, Chan H, Hunt M, et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006;176:1415–1419
  9. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  10. Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy-78 Gy. Int J Radiat Oncol Biol Phys. 2005;61:1019–1034
  11. Merrick GS, Butler WM, Wallner KE, et al. Rectal function following brachytherapy with or without supplemental external beam radiation: results of two prospective randomized trials. Brachytherapy. 2003;2:147–157
  12. Merrick GS, Butler WM, Wallner KE, et al. Late rectal function after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;57:42–48
  13. Feigenberg SJ, Lee WR, Desilvio ML, et al. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Radiat Oncol Biol Phys. 2005;62:956–964
  14. Lee WR, Hall MC, McQuellon RP, et al. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:614–623
  15. Litwin MS, Gore JL, Kwan L, et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer. 2007;109:2239–2247

PII: S0090-4295(08)01603-8

doi: 10.1016/j.urology.2008.09.029

Urology
Volume 73, Issue 3 , Pages 470-472 , March 2009

Article Tools